Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(4):702–704. doi: 10.1038/sj.bjc.6690751

Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast

S Regele 1, P Kohlberger 2, F D Vogl 1, W Böhm 1, R Kreienberg 1, I B Runnebaum 2
PMCID: PMC2362899  PMID: 10574259

Abstract

Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of ≤ 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological subtype, tumour size, grading, p53 immunohistochemistry or hormone receptor status. © 1999 Cancer Research Campaign

Keywords: breast cancer, ductal carcinoma in situ, p53, autoantibodies

Full Text

The Full Text of this article is available as a PDF (40.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  2. Angelopoulou K., Stratis M., Diamandis E. P. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer. 1997 Jan 6;70(1):46–51. doi: 10.1002/(sici)1097-0215(19970106)70:1<46::aid-ijc7>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  3. Coles C., Condie A., Chetty U., Steel C. M., Evans H. J., Prosser J. p53 mutations in breast cancer. Cancer Res. 1992 Oct 1;52(19):5291–5298. [PubMed] [Google Scholar]
  4. Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982 Oct 15;30(4):403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  5. Davidoff A. M., Iglehart J. D., Marks J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3439–3442. doi: 10.1073/pnas.89.8.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Holland R., Hendriks J. H. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol. 1994 Aug;11(3):181–192. [PubMed] [Google Scholar]
  7. Lagios M. D. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am. 1990 Aug;70(4):853–871. doi: 10.1016/s0039-6109(16)45185-6. [DOI] [PubMed] [Google Scholar]
  8. Maass J. D., Gottschlich S., Lippert B. M., Niemann A. M., Görögh T., Werner J. A. Antikörperbildung gegen das zelluläre Protein p53 bei Patienten mit Plattenepithelkarzinomen der oberen Luft- und Speisewege. Laryngorhinootologie. 1996 Jan;75(1):53–56. doi: 10.1055/s-2007-997532. [DOI] [PubMed] [Google Scholar]
  9. Mudenda B., Green J. A., Green B., Jenkins J. R., Robertson L., Tarunina M., Leinster S. J. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer. 1994 Jun;69(6):1115–1119. doi: 10.1038/bjc.1994.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Peeters P. H., Verbeek A. L., Hendriks J. H., van Bon M. J. Screening for breast cancer in Nijmegen. Report of 6 screening rounds, 1975-1986. Int J Cancer. 1989 Feb 15;43(2):226–230. doi: 10.1002/ijc.2910430209. [DOI] [PubMed] [Google Scholar]
  11. Peyrat J. P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 1995 Mar 11;345(8950):621–622. doi: 10.1016/s0140-6736(95)90523-5. [DOI] [PubMed] [Google Scholar]
  12. Remmele W., Stegner H. E. Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe. 1987 May;8(3):138–140. [PubMed] [Google Scholar]
  13. Runnebaum I. B., Nagarajan M., Bowman M., Soto D., Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10657–10661. doi: 10.1073/pnas.88.23.10657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992 Nov 15;52(22):6380–6384. [PubMed] [Google Scholar]
  15. Schnitt S. J., Silen W., Sadowsky N. L., Connolly J. L., Harris J. R. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med. 1988 Apr 7;318(14):898–903. doi: 10.1056/NEJM198804073181406. [DOI] [PubMed] [Google Scholar]
  16. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  17. Winter S. F., Minna J. D., Johnson B. E., Takahashi T., Gazdar A. F., Carbone D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992 Aug 1;52(15):4168–4174. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES